Quantitating ADCC against adherent cells: Impedance‐based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response
Authors:
Open Access
- 25 September 2017
- journal article
- research article
- Published by Wiley in Cytometry Part A
- Vol. 91 (10) , 1021-1029
Abstract
Monoclonal antibody‐based immunotherapeutics will dominate Pharma's next generation of blockbuster drugs, and Fc‐associated functions, including antibody dependent cellular cytotoxicity (ADCC) are among the highly desired activities mediated by these antibodies. Therefore, quantitative evaluation of ADCC is required during drug development. Our objective was to find the most suitable and reliable nonradioactive method for quantitative analysis of in vitro ADCC against adherent cells, which often serve as models for solid tumors. The test system was comprised the HER2 positive JIMT‐1 cells targeted by the specific therapeutic antibodies trastuzumab (Herceptin®) and pertuzumab (Perjeta®). These cells are resistant to the direct biological effects of these antibodies, and, therefore, allow the isolated assessment of ADCC. We compared fluorescein diacetate (FDA) and carboxyfluorescein diacetate succinimidyl ester (CFSE) release as a fluorescent alternative to 51Cr release; propidium iodide (PI) uptake revealing increased membrane permeability; the PanToxiLux assay measuring ADCC induced pro‐apoptotic protease activity in flow cytometry; and an impedance‐based real time cell adhesion test. We found that release assays are compromised by high spontaneous release of the label. PI uptake could not differentiate well between spontaneous NK activity and specific ADCC. The PanToxiLux assay, besides allowing for shorter assay times, offers improvement over the previous approaches in distinguishing spontaneous and antibody mediated NK action, but, probably owed to the prolonged detached state of adherent target cells, only at highly saturating antibody concentrations. In the case of adherent target cells, impedance‐based cell analysis attains functional information exclusively on the target cells without having to label them for distinguishing from effectors or assay readout. It also allows continuous monitoring for days, and specifically detects target cell detachment, as the final functional consequence of ADCC. The sensitivity of this method even allows for quantitating the additivity and saturability of ADCC as a function of antibody concentration. We conclude that impedance‐based assays are the most sensitive for quantitatively assessing in vitro ADCC on adherent target cells. © 2017 International Society for Advancement of CytometryKeywords
Funding Information
- European Regional Development Fund (TÁMOP‐4.2.2.A‐11/1/KONV‐2012‐0025, GINOP‐2.3.2‐15‐2016‐00020)
This publication has 28 references indexed in Scilit:
- Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cellsOncoImmunology, 2012
- Real-time label-free monitoring of adipose-derived stem cell differentiation with electric cell-substrate impedance sensingProceedings of the National Academy of Sciences, 2011
- Use of electric cell–substrate impedance sensing to assess in vitro cytotoxicityBiosensors and Bioelectronics, 2009
- Cytotoxicity of Metal and Semiconductor Nanoparticles Indicated by Cellular MicromotilityACS Nano, 2008
- A bioluminescent cytotoxicity assay for assessment of membrane integrity using a proteolytic biomarkerToxicology in Vitro, 2008
- ErbB-directed immunotherapy: Antibodies in current practice and promising new agentsImmunology Letters, 2008
- Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumorCancer Letters, 2008
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistanceMolecular Cancer Therapeutics, 2007
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003